393 related articles for article (PubMed ID: 15590644)
1. Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice.
Hojjati MR; Li Z; Zhou H; Tang S; Huan C; Ooi E; Lu S; Jiang XC
J Biol Chem; 2005 Mar; 280(11):10284-9. PubMed ID: 15590644
[TBL] [Abstract][Full Text] [Related]
2. Serine palmitoyltransferase inhibitor myriocin induces the regression of atherosclerotic plaques in hyperlipidemic ApoE-deficient mice.
Park TS; Rosebury W; Kindt EK; Kowala MC; Panek RL
Pharmacol Res; 2008 Jul; 58(1):45-51. PubMed ID: 18611440
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice.
Park TS; Panek RL; Mueller SB; Hanselman JC; Rosebury WS; Robertson AW; Kindt EK; Homan R; Karathanasis SK; Rekhter MD
Circulation; 2004 Nov; 110(22):3465-71. PubMed ID: 15545514
[TBL] [Abstract][Full Text] [Related]
4. Serine palmitoyl-CoA transferase (SPT) deficiency and sphingolipid levels in mice.
Hojjati MR; Li Z; Jiang XC
Biochim Biophys Acta; 2005 Oct; 1737(1):44-51. PubMed ID: 16216550
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of atherosclerosis by the serine palmitoyl transferase inhibitor myriocin is associated with reduced plasma glycosphingolipid concentration.
Glaros EN; Kim WS; Wu BJ; Suarna C; Quinn CM; Rye KA; Stocker R; Jessup W; Garner B
Biochem Pharmacol; 2007 May; 73(9):1340-6. PubMed ID: 17239824
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of sphingolipid synthesis improves dyslipidemia in the diet-induced hamster model of insulin resistance: evidence for the role of sphingosine and sphinganine in hepatic VLDL-apoB100 overproduction.
Dekker MJ; Baker C; Naples M; Samsoondar J; Zhang R; Qiu W; Sacco J; Adeli K
Atherosclerosis; 2013 May; 228(1):98-109. PubMed ID: 23466071
[TBL] [Abstract][Full Text] [Related]
7. Serine palmitoyltransferase is the primary target of a sphingosine-like immunosuppressant, ISP-1/myriocin.
Miyake Y; Kozutsumi Y; Nakamura S; Fujita T; Kawasaki T
Biochem Biophys Res Commun; 1995 Jun; 211(2):396-403. PubMed ID: 7794249
[TBL] [Abstract][Full Text] [Related]
8. Effects of sphingolipid synthesis inhibition on cholesterol gallstone formation in C57BL/6J mice.
Lee BJ; Kim JS; Kim BK; Jung SJ; Joo MK; Hong SG; Kim JS; Kim JH; Yeon JE; Park JJ; Byun KS; Bak YT; Yoo HS; Oh S
J Gastroenterol Hepatol; 2010 Jun; 25(6):1105-10. PubMed ID: 20594226
[TBL] [Abstract][Full Text] [Related]
9. Serine palmitoyltransferase (SPT) deficient mice absorb less cholesterol.
Li Z; Park TS; Li Y; Pan X; Iqbal J; Lu D; Tang W; Yu L; Goldberg IJ; Hussain MM; Jiang XC
Biochim Biophys Acta; 2009 Apr; 1791(4):297-306. PubMed ID: 19416652
[TBL] [Abstract][Full Text] [Related]
10. Reduction of ceramide de novo synthesis in solid tissues changes sphingolipid levels in rat plasma, erythrocytes and platelets.
Błachnio-Zabielska A; Baranowski M; Wójcik B; Górski J
Adv Med Sci; 2016 Mar; 61(1):72-7. PubMed ID: 26521206
[TBL] [Abstract][Full Text] [Related]
11. Myriocin and d-PDMP ameliorate atherosclerosis in ApoE-/- mice via reducing lipid uptake and vascular inflammation.
Yu Z; Peng Q; Li S; Hao H; Deng J; Meng L; Shen Z; Yu W; Nan D; Bai Y; Huang Y
Clin Sci (Lond); 2020 Mar; 134(5):439-458. PubMed ID: 32091078
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of serine palmitoyltransferase by myriocin, a natural mycotoxin, causes induction of c-myc in mouse liver.
He Q; Johnson VJ; Osuchowski MF; Sharma RP
Mycopathologia; 2004 Apr; 157(3):339-47. PubMed ID: 15180163
[TBL] [Abstract][Full Text] [Related]
13. Myriocin, a serine palmitoyltransferase inhibitor, alters regional brain neurotransmitter levels without concurrent inhibition of the brain sphingolipid biosynthesis in mice.
Osuchowski MF; Johnson VJ; He Q; Sharma RP
Toxicol Lett; 2004 Feb; 147(1):87-94. PubMed ID: 14700532
[TBL] [Abstract][Full Text] [Related]
14. Rewiring Endothelial Sphingolipid Metabolism to Favor S1P Over Ceramide Protects From Coronary Atherosclerosis.
Manzo OL; Nour J; Sasset L; Marino A; Rubinelli L; Palikhe S; Smimmo M; Hu Y; Bucci MR; Borczuk A; Elemento O; Freed JK; Norata GD; Di Lorenzo A
Circ Res; 2024 Apr; 134(8):990-1005. PubMed ID: 38456287
[TBL] [Abstract][Full Text] [Related]
15. Myriocin slows the progression of established atherosclerotic lesions in apolipoprotein E gene knockout mice.
Glaros EN; Kim WS; Quinn CM; Jessup W; Rye KA; Garner B
J Lipid Res; 2008 Feb; 49(2):324-31. PubMed ID: 17978313
[TBL] [Abstract][Full Text] [Related]
16. Modulation of lipoprotein metabolism by inhibition of sphingomyelin synthesis in ApoE knockout mice.
Park TS; Panek RL; Rekhter MD; Mueller SB; Rosebury WS; Robertson A; Hanselman JC; Kindt E; Homan R; Karathanasis SK
Atherosclerosis; 2006 Dec; 189(2):264-72. PubMed ID: 16458317
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Sphingolipid Synthesis as a Phenotype-Modifying Therapy in Cystic Fibrosis.
Mingione A; Dei Cas M; Bonezzi F; Caretti A; Piccoli M; Anastasia L; Ghidoni R; Paroni R; Signorelli P
Cell Physiol Biochem; 2020 Jan; 54(1):110-125. PubMed ID: 31999897
[TBL] [Abstract][Full Text] [Related]
18. Sphingolipids and atherosclerosis: a mechanistic connection? A therapeutic opportunity?
Tabas I
Circulation; 2004 Nov; 110(22):3400-1. PubMed ID: 15569847
[No Abstract] [Full Text] [Related]
19. The effect of dietary sphingolipids on plasma sphingomyelin metabolism and atherosclerosis.
Li Z; Basterr MJ; Hailemariam TK; Hojjati MR; Lu S; Liu J; Liu R; Zhou H; Jiang XC
Biochim Biophys Acta; 2005 Jul; 1735(2):130-4. PubMed ID: 15967715
[TBL] [Abstract][Full Text] [Related]
20. Serine palmitoyltransferase inhibitor myriocin induces growth inhibition of B16F10 melanoma cells through G(2) /M phase arrest.
Lee YS; Choi KM; Choi MH; Ji SY; Lee S; Sin DM; Oh KW; Lee YM; Hong JT; Yun YP; Yoo HS
Cell Prolif; 2011 Aug; 44(4):320-9. PubMed ID: 21645154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
